Table 1

Baseline sociodemographic, clinical, and laboratory characteristics of RA patients in the CLEAR registries as a function of the presence of erosions or rheumatoid nodules

Radiographic erosions

Rheumatoid nodules



Variable

Present n = 185

Absent n = 276

Pf

Present n = 156

Absent n = 593

Pf


Age at RA onset, years, mean (SD)

45.3 (14.5)

48.3 (12.6)

0.02

45.6 (12.6)

47.8 (13.6)

0.06

Disease duration,a years, median (IQRb)

3.8 (1.2-15.5)

1.2 (6.0-2.0)

<0.0001

7.5 (1.3-15.6)

1.8 (0.8-8.0)

<0.001

Smoking, ever,c n (%)

98 (54.4)

139 (51.9)

0.59

95 (61.7)

295 (50.3)

0.01

HAQd score, median (IQR)

2.0 (1.3-2.4)

1.8 (0.9-2.4)

0.27

2.1 (1.3-2.6)

1.8 (1.0-2.4)

0.01

Joint-space narrowing at baseline, present (score >0), n (%)

132 (71.4)

34 (12.3)

<0.001

48 (53.3)

116 (31.9)

<0.001

Rheumatoid factor positive, n (%)

145 (87.3)

182 (74.3)

0.001

127 (90.7)

418 (77.1)

<0.001

Anti-CCP antibody positive, n (%)

148 (81.3)

159 (59.3)

<0.001

127 (84.1)

375 (65.2)

<0.001

Abnormal C-reactive protein (>5 mg/L), n (%)

94 (51.9)

126 (46.5)

0.26

77 (58.8)

238 (44.7)

<0.004

HLA-DRB1 present,e n (%)

78 (42.9)

113 (41.1)

0.71

64 (43.2)

234 (39.9)

0.45

Methotrexate use, ever,c n (%)

149 (82.3)

175 (64.6)

<0.001

127 (81.9)

423 (72.2)

0.01


aDisease duration at enrollment: duration between self-reported onset of symptoms and date of enrollment; bIQR interquartile range (25th and 75th); ccurrent or past; dHeath Assessment Questionnaire; eHLADRB1 was made to determine SE positive; fTwo-tailed P value by independent-sample t test, Wilcoxon rank-sum test, or χ2 test for proportions, as appropriate and wherever applicable, missing data were excluded from the denominator for calculating percentage and P value.

Burgos et al. Arthritis Research & Therapy 2010 12:R75   doi:10.1186/ar2994

Open Data